Catalog product

Codex DNA Expands Catalog of COVID-19 Tools with Publication of Full Synthetic Genome for Omicron Variant of SARS-CoV-2

Researchers around the world can use the synthetic genome to produce a virus to test strain-specific diagnostics, monoclonal antibody treatments, small molecule therapies, or new vaccines against the highly transmissible variant.

SAN DIEGO, December 23, 2021 (GLOBE NEWSWIRE) – Codex DNA, Inc. (Nasdaq: DNAY), a pioneer of automated bench-top synthetic biology systems, today announced the release of a new complete synthetic genome of SARS- CoV -2 virus for the highly mutated and contagious Omicron variant (line B.1.1.529). Omicron has been identified as a variant of concern by the WHO and is spreading faster than any previous variant of SARS-CoV-2. The genome was constructed with the company’s BioXp ™ 3250 system, a fully automated synthetic biology lab workstation for fast, accurate, and reproducible writing of DNA and mRNA.

“The Codex DNA team applauds the excellent work being done by scientists in South Africa to rapidly identify and characterize the latest variant of SARS-CoV-2 of concern, and we aim to honor their efforts by releasing this new synthetic genome. to expand access to research in laboratories. around the world, ”said Todd R. Nelson, PhD, CEO of Codex DNA. “This synthetic version of Omicron reflects our continued commitment to providing useful tools and resources to scientists fighting the COVID-19 pandemic. “

With the Omicron variant, Codex DNA offers a comprehensive catalog of 14 synthetic SARS-CoV-2 genomes as well as bespoke SARS-CoV-2 genomes that are used to help researchers in their search for solutions to combat specific variants. In addition, Codex DNA offers personalized DNA synthesis services to deal with the global pandemic. For customers interested in alternative variants to SARS-CoV-2, Codex DNA provides a wide range of synthetic controls that allow scientists to confidently verify and validate assays without the need for clinical virus samples.

All synthetic genomes produced by Codex DNA are made in the United States and are available to researchers who go through a rigorous biosafety screening process to ensure their responsible use. For more information on the Codex DNA tool portfolio to combat SARS-CoV-2, please visit

About Codex DNA

Codex DNA empowers scientists to create new synthetic biology-based solutions to address many of humanity’s greatest challenges. As the inventors of the industry standard Gibson assembly® and the first commercial, automated bench-top DNA and mRNA synthesis system, Codex DNA enables rapid, accurate and reproducible writing of DNA and mRNA for many downstream markets. The company’s award-winning BioXp ™ system consolidates, automates and optimizes the entire synthesis, cloning and amplification workflow. As a result, it offers virtually error-free large-scale DNA / RNA synthesis in days and hours instead of weeks or months. Scientists around the world are using the technology in their own labs to accelerate the design-build-test paradigm of new, high-value products for precision medicine, biologic drug discovery, vaccine and treatment development, genome editing and cell and gene therapy. Codex DNA is a public company based in San Diego. For more information visit

Forward-looking statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements are based on the beliefs and assumptions of Codex DNA and on the information currently available to it as of the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Codex DNA actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements. These statements include, but are not limited to, statements regarding the ability of Codex DNA to generate synthetic SARS-CoV-2 genomes and their utility in COVID-19 diagnostics and therapeutic discovery. These and other risks are described in more detail in documents filed by Codex DNA with the Securities and Exchange Commission (“SEC”) and in other documents that Codex DNA subsequently files with the SEC from time to time. other. Except to the extent required by law, Codex DNA assumes no obligation to update these statements to reflect events which occur or circumstances which exist after the date on which they were made.

Richard lepke
Director of Investor Relations
(619) 840-5392
[email protected] Complete-synthetic-genome-for-SARS-CoV-2-Omicron-Variant.html